Lundbeck to acquire Abide Therapeutics

7 May 2019

Danish CNS specialist Lundbeck (LUND: CO) on Monday announced the signing of a definitive agreement into acquire La Jolla, USA-based Abide Therapeutics.

Under the terms of the agreement, Lundbeck may pay $250 million upfront with a commitment to pay future development and sales milestones to the group of current owners of up to $150 million. This acquisition provides Lundbeck a novel discovery platform and a USA-based research hub.

The transaction is expected to be financed by Lundbeck's existing cash reserves and is scheduled to close during the second quarter of 2019. News of the deal saw Lundbeck’s shares dip 1.36% to 283.00 Danish kroner by late morning trading.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK